Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Caplin Point Laboratories's enterprise value is ₹185,415 Mil.
Caplin Point Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹8,764 Mil. Therefore, Caplin Point Laboratories's EV-to-EBITDA for today is 21.16.
The historical rank and industry rank for Caplin Point Laboratories's EV-to-EBITDA or its related term are showing as below:
NSE:CAPLIPOINT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.17 Med: 14.83 Max: 33.51
Current: 21.17
During the past 13 years, the highest EV-to-EBITDA of Caplin Point Laboratories was 33.51. The lowest was 6.17. And the median was 14.83.
NSE:CAPLIPOINT's EV-to-EBITDA is ranked worse than 69.15% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.37
vs NSE:CAPLIPOINT: 21.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Caplin Point Laboratories (NSE:CAPLIPOINT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Caplin Point Laboratories's PE Ratio (TTM) for today is calculated as:
Caplin Point Laboratories's share price for today is ₹2574.10.
Caplin Point Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹84.100.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's EV-to-EBITDA falls into.
Caplin Point Laboratories's current Enterprise Value is ₹185,415 Mil.
Caplin Point Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,764 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caplin Point Laboratories (NSE:CAPLIPOINT) has a EV-to-EBITDA of 21.16 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Caplin Point Laboratories. This is 43% above median its historical median of 14.83. Over the past decade, Caplin Point Laboratories' EV-to-EBITDA has ranged from 6.17 to 33.51. According to the industry distribution chart, Caplin Point Laboratories ranks #511 out of 739 companies in the Drug Manufacturers industry, placing it in the top 69.1%.
Is Caplin Point Laboratories' EV-to-EBITDA too high?
Caplin Point Laboratories' current EV-to-EBITDA of 21.16 is 43% above median its 10-year median of 14.83. Over the past 10 years, this metric has ranged from a low of 6.17 to a high of 33.51. The Drug Manufacturers industry median EV-to-EBITDA is 13.37. Caplin Point Laboratories' value of 21.16 is 58.3% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #511 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Caplin Point Laboratories has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #511 out of 739 companies for EV-to-EBITDA. This places Caplin Point Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 13.37. Caplin Point Laboratories' value of 21.16 is 58.3% above this benchmark. Historically, Caplin Point Laboratories' own EV-to-EBITDA has ranged from 6.17 to 33.51 over the past decade. While the company's 10-year median is 14.83 vs. the industry median of 13.37, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.37, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current EV-to-EBITDA of 21.16 is 58.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Caplin Point Laboratories. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current EV-to-EBITDA is 21.16, which is 43% above median its own 10-year median of 14.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,106.00, compared to a current price of ₹2,574.10 — trading 22.2% above its estimated fair value. The current EV-to-EBITDA is 21.16, which is 43% above median its 10-year median of 14.83 and 58.3% above the Drug Manufacturers industry median of 13.37. Caplin Point Laboratories' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current EV-to-EBITDA is 21.16 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,574.10 is trading 22.2% above its estimated GF Value™ of ₹2,106.00.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
EV-to-EBITDA: 21.16 (43% above median its 10-year median of 14.83)
GF Value™: ₹2,106.00 vs. price of ₹2,574.10 (22.2% above fair value)
Industry Position: 58.3% above the Drug Manufacturers median (#511 of 739)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
87GF Score
Get the complete analysis for NSE:CAPLIPOINT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
